Primary salivary gland-type tumours of the lung are rare [
1] and differ from the more common types of lung cancer. As the main type of salivary gland-type lung carcinoma, PACC is difficult to diagnose and cure at the early stage and is unlikely to be completely surgically removed. Postoperative radiotherapy is helpful for reducing the likelihood of recurrence and metastasis [
20]. However, only limited data are available on the role of conventional systemic and targeted therapies in the management of patients with advanced disease. There is perhaps a need to develop new molecular biomarkers to improve the therapeutic options for these patients. Recently, important advances have been made in ACC; a signature t(6;9)(q22–23; p23–24) chromosomal translocation resulting in a MYB–NFIB fusion gene was identified, and the fusion oncoprotein activates the transcription of MYB targets that are important for oncogenic transformation. An increasing number of studies has demonstrated that MYB activation occurs in more than 80 % of cases of ACC, including PACC [
4]. In this study, we aimed to identify driver genes other than MYB in PACC.
Genetic alterations associated with the development of NSCLC have been extensively characterized. The driver genes involved in lung adenocarcinoma include KRAS, EGFR, ALK, and BRAF [
2], and those implicated in lung squamous cell carcinoma (LSCC) include PIK3CA, FGFR1, EGFR, PDGFRA, and DDR2 [
3]. However, the mutational status of these genes in PACC has not been well characterized. Activating mutations in EGFR identify those NSCLC patients with an improved clinical response to tyrosine kinase inhibitor (TKI) therapy, but it remains unknown whether patients with PACC harbour EGFR mutations and can thus benefit from TKI therapy. EGFR mutations have been reported in pulmonary and salivary mucoepidermoid carcinoma [
21], but they are rare in ACC of the salivary gland [
14,
15], and no EGFR mutations were detected in PACC in a previous study [
18]. Similarly, in our series, no mutations in EGFR were detected. A few studies have identified alterations in KRAS in ACC [
7,
12,
13], and KRAS alterations were reported to be more common than other gene alterations, with the exception of MYB, in a recent study [
12]; however, KRAS mutations were absent in other studies that involved whole exome sequencing of ACC [
16] and next-generation sequencing [
15]. There are no relevant studies on KRAS in PACC in the literature, and KRAS mutations were not detected in our series. Genetic alterations in PIK3CA [
8,
11,
15,
16] and BRAF [
10,
13] have been detected in ACC at a lower frequency than KRAS, and a study suggested that the PI3K/AKT pathway may be responsible for the unusually aggressive course of ACC [
8]. There are no similar relevant studies in PACC, and no PIK3CA and BRAF gene mutations were detected in our series. ALK gene alterations mainly occur in lung adenocarcinoma and are associated with gene rearrangements. ALK inhibitors exhibit marked anti-tumour activity against lung cancers with ALK rearrangements [
22]. However, emerging genomic data are revealing common ALK point mutations in various cancer types other than lung cancer, and several recent studies have demonstrated that ALK point mutations, independent of ALK gene rearrangements, can be oncogenic [
23]. Genetic alterations of DDR2 and PDGFRA are associated with the development of LSCC [
3,
24,
25]. Recently, DDR2 mutations were reported in approximately 4 % of LSCC cases, and some of these mutations induced oncogenic transformation. DDR2 mutations are associated with increased sensitivity to dasatinib, and the clinical activity of dasatinib in lung cancer is being evaluated in numerous clinical trials [
24]. Platelet-derived growth factor receptors (PDGFRs) and their ligands play critical roles in several human malignancies. Sunitinib is a clinically approved, multi-targeted TKI that inhibits PDGFR with demonstrated clinical activity in gastrointestinal stromal tumours. However, some rare tumours, including LSCC, that demonstrate PDGFRA activation may also be clinically responsive to pharmacologic PDGFRA inhibition [
25]. However, alterations in the ALK and DDR2 genes have not yet been investigated in ACC, and PDGFRA was only detected in two ACC cases [
15]. In our series, there were no mutations in the ALK, DDR2, and PDGFRA genes. Our study suggested that the genetic mutations associated with PACC are different from those implicated in NSCLC, and EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 might not be driver genes in PACC.
In conclusion, the genetic mutations associated with PACC are different from those implicated in non-small cell lung cancer, and EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 may not be driver genes in PACC; we must identify other genes for targeted therapy against PACC.